The University of Pittsburgh and UPMC hope research technologies will make it to market much faster by way of a new commercialization agreement between the two institutions.
The key to the Pitt-UPMC partnership, announced Friday morning, is a pre-drafted commercialization agreement template that could eliminate weeks or even months of negotiation between researchers and the hospital system. It stipulates terms for licensing, royalty arrangements and equity in new companies, among other potential considerations.
The goal, said Marc Malandro, director of Pitt’s Innovation Institute, is to “get these treatments to patients as fast as possible” by giving researchers a built-in licensing partner with built-in terms.
Pitt and UPMC already collaborate when it comes to research, Mr. Malandro said, given that so many UPMC physicians are also faculty members and researchers at the University of Pittsburgh School of Medicine.
But research is one thing; getting that research into wider application is another. The agreement could help push promising technologies out of the “valley of death,” which is the metaphor often used to describe the gap between university research and its commercialization (or its failure).
“It’s a very long process sometimes,” said David Schwartz, co-founder and president of 2Market Information, an Atlanta publishing company that focuses on technology transfer issues.
“Ninety-five percent or more of the [projects] that take place never really see the light of day, for a variety of reasons,” Mr. Schwartz said.
Pitt and UPMC have been working on the agreement since autumn, and they also announced that the first technology to be licensed by UPMC Enterprises (the health system’s commercialization arm) is a genetic discovery that could lead to more accurate tests for aggressive prostate cancer.
Tal Heppenstall Jr., treasurer at UPMC and also president of UPMC Enterprises, said the streamlined commercialization agreement might “actually encourage the Pitt faculty to come forward with ideas,” rather than seek other investors or commercial partners.
The agreement isn’t exclusive — meaning Pitt can still work with other commercial partners, and UPMC can still work with other technology developers. In other words, if Pitt researchers come up with a new drug, they probably would partner with a pharmaceutical firm, not UPMC, Mr. Malandro said.
“I don’t think [this] ties anyone’s hands,” he said.
Pitt and UPMC, according to the announcement, “will meet regularly to discuss research projects underway and medical needs based on clinical experience.”
Mr. Schwartz, the 2Market founder, said the arrangement was a novel one, and said regular meetings would help give researchers a frequent audience with financiers and vice versa. That familiarity could lead to more targeted research and investment, and “solves the marketing challenge” for Pitt faculty.
”It’s better than playing roulette,” he said. UPMC can say, “This one’s interesting, let’s push the button, [and] we already know what the terms are ... that takes a huge amount of time and effort out of the equation.”




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.